A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma(waveLINE-004)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501243-33-00

Acronym

MK2140-004

Enrollment

Registered

2023-04-27

Start date

2022-02-03

Completion date

Unknown

Last updated

2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse Large B Cell Lymphoma (a type of non-Hodgkin’s lymphoma, in patients who failed prior therapies)

Brief summary

Objective Response Rate (ORR) per Lugano Response Criteria

Detailed description

Duration of Response (DOR) per Lugano Response Criteria 1, Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE

Interventions

DRUGZilovertamab vedotin

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR) per Lugano Response Criteria	—

Secondary

Measure	Time frame
Duration of Response (DOR) per Lugano Response Criteria 1, Number of Participants Who Experience an Adverse Event (AE), Number of Participants Who Discontinue Study Treatment Due to an AE	—

Countries

Czechia, Estonia, France, Greece, Italy, Norway, Poland, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026